

Michael Boe MÃller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8158475/publications.pdf>

Version: 2024-02-01

176
papers

7,407
citations

61977

43
h-index

60616

81
g-index

184
all docs

184
docs citations

184
times ranked

8417
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	1.4	596
2	Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3460-3467.	1.6	590
3	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	1.4	301
4	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2012, 26, 2103-2113.	7.2	301
5	Malignant Transformation of Neurofibromas in Neurofibromatosis 1 Is Associated with CDKN2A/p16 Inactivation. <i>American Journal of Pathology</i> , 1999, 155, 1879-1884.	3.8	235
6	Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation – a population-based study of 1575 cases. <i>British Journal of Haematology</i> , 2004, 124, 151-159.	2.5	207
7	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	1.4	206
8	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	1.4	173
9	Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 180-188.	2.8	157
10	Epidemiology of systemic mastocytosis in Denmark. <i>British Journal of Haematology</i> , 2014, 166, 521-528.	2.5	154
11	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	3.5	142
12	The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype. <i>European Journal of Haematology</i> , 2007, 79, 508-515.	2.2	130
13	High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 612-619.	3.7	127
14	Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. <i>European Journal of Cancer</i> , 1994, 30, 1760-1764.	2.8	118
15	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	7.0	117
16	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	5.5	112
17	DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. <i>Blood</i> , 2017, 130, 554-557.	1.4	110
18	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.4	106

#	ARTICLE	IF	CITATIONS
19	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	1.4	97
20	Sensitive <i>KIT</i> D816V mutation analysis of blood as a diagnostic test in mastocytosis. <i>American Journal of Hematology</i> , 2014, 89, 493-498.	4.1	96
21	Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1379-1388.	1.6	94
22	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	1.8	93
23	Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. <i>Leukemia Research</i> , 2013, 37, 1041-1045.	0.8	84
24	Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. <i>Leukemia</i> , 1999, 13, 453-459.	7.2	82
25	Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 6638-6649.	1.4	79
26	Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. <i>Hematology</i> , 2009, 14, 331-334.	1.5	76
27	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	1.8	72
28	Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. <i>Leukemia</i> , 2000, 14, 1727-1735.	7.2	70
29	p27 in Cell Cycle Control and Cancer. <i>Leukemia and Lymphoma</i> , 2000, 39, 19-27.	1.3	65
30	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	64
31	Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. <i>American Journal of Hematology</i> , 2016, 91, 1069-1075.	4.1	62
32	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	1.8	61
33	FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. <i>Leukemia</i> , 2016, 30, 605-616.	7.2	61
34	R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. <i>Annals of Oncology</i> , 2012, 23, 147-153.	1.2	60
35	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.0	60
36	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	59

#	ARTICLE	IF	CITATIONS
37	Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. <i>Leukemia</i> , 2000, 14, 898-904.	7.2	56
38	Serum tryptase correlates with the <i>KIT</i> D816V mutation burden in adults with indolent systemic mastocytosis. <i>European Journal of Haematology</i> , 2013, 91, 106-111.	2.2	51
39	Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. <i>European Journal of Haematology</i> , 2007, 79, 501-507.	2.2	50
40	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	5.5	48
41	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	7.0	48
42	Recognizing mastocytosis in patients with anaphylaxis: Value of <i>KIT</i> D816V mutation analysis of peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 262-264.	2.9	47
43	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 2630-2640.	1.4	46
44	Circulating <i>KIT</i> <i>D816V</i> mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. <i>European Journal of Haematology</i> , 2012, 89, 42-46.	2.2	44
45	Reduced expression of <i>TRIM21</i> /Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. <i>Journal of Internal Medicine</i> , 2015, 278, 323-332.	6.0	43
46	Microarray-based classification of diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2005, 74, 453-465.	2.2	42
47	High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma. <i>Histopathology</i> , 2014, 65, 490-500.	2.9	42
48	TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma. <i>Histopathology</i> , 2017, 71, 98-111.	2.9	42
49	Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. <i>Annals of Hematology</i> , 2008, 87, 847-850.	1.8	41
50	Quantitative assessment of the <i>JAK2 V617F</i> allele burden: equivalent levels in peripheral blood and bone marrow. <i>Leukemia</i> , 2008, 22, 194-195.	7.2	41
51	Single nucleotide variation in the TP53 untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	1.4	41
52	<i>KIT</i> D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 723-728.	2.9	40
53	Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2015, 26, 393-399.	1.2	39
54	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	3.8	39

#	ARTICLE	IF	CITATIONS
55	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.5	39
56	NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression*. <i>European Journal of Haematology</i> , 2011, 87, 400-408.	2.2	36
57	Proteasome inhibitors and <scp>IM</scp>iDs can overcome some highâ€risk cytogenetics in multiple myeloma but not gain 1q21. <i>European Journal of Haematology</i> , 2016, 96, 46-54.	2.2	35
58	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	1.8	35
59	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	1.8	33
60	Cyclin D3 Expression in Non-Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2001, 115, 404-412.	0.7	32
61	Prognostic significance of metallothionein in B-cell lymphomas. <i>Blood</i> , 2006, 108, 3514-3519.	1.4	32
62	Prevalence and clinical implications of cyclin D1 expression in diffuse large Bâ€cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximabâ€CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	4.1	32
63	Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2015, 56, 1677-1685.	1.3	32
64	Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. <i>Histopathology</i> , 2002, 41, 322-330.	2.9	29
65	RelA NF-ÎB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	3.1	29
66	Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. <i>British Journal of Haematology</i> , 2006, 133, 43-49.	2.5	28
67	Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. <i>Leukemia and Lymphoma</i> , 2014, 55, 911-919.	1.3	27
68	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Leukemia</i> , 2014, 28, 362-372.	7.2	27
69	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	17.0	27
70	Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 806-808.	2.9	25
71	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
72	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2013, 66, 956-961.	2.0	24

#	ARTICLE	IF	CITATIONS
73	Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. <i>British Journal of Haematology</i> , 1999, 105, 730-736.	2.5	23
74	Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?. <i>Oncotarget</i> , 2014, 5, 1912-1925.	1.8	23
75	Conditional survival of patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2006, 106, 2165-2170.	4.1	22
76	Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. <i>Hematology</i> , 2009, 14, 11-15.	1.5	22
77	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
78	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	5.2	22
79	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	7.0	22
80	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	5.5	21
81	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , 2016, 96, 602-612.	1.3	21
82	Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. <i>Apmis</i> , 2015, 123, 652-658.	2.0	20
83	Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. <i>Transplant International</i> , 2016, 29, 483-493.	1.6	20
84	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	3.4	20
85	Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL. <i>PLoS ONE</i> , 2015, 10, e0115538.	2.5	19
86	A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. <i>Leukemia and Lymphoma</i> , 2015, 56, 2556-2562.	1.3	19
87	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	3.1	19
88	Clinical Relevance of Sensitive and Quantitative STAT3 Mutation Analysis Using Next-Generation Sequencing in T-Cell Large Granular Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 382-392.	2.8	18
89	Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. <i>British Journal of Haematology</i> , 2013, 161, 373-382.	2.5	17
90	High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2015, 39, 555-560.	0.8	17

#	ARTICLE	IF	CITATIONS
91	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	5.5	17
92	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I κ -CBF) Tj ETQg 0 0 rgBT /Overlo	2.8	17
93	High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. <i>Hematology</i> , 2008, 13, 71-76.	1.5	16
94	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. <i>Haematologica</i> , 2020, 105, 2432-2439.	3.5	16
95	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. <i>Oncotarget</i> , 2016, 7, 52940-52956.	1.8	16
96	Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. <i>Hematological Oncology</i> , 2015, 33, 120-128.	1.7	15
97	NF- κ B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. <i>Modern Pathology</i> , 2017, 30, 854-876.	5.5	15
98	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. <i>Pathology</i> , 2017, 49, 731-739.	0.6	15
99	Validation of Putative Reference Genes for Normalization of Q-RT-PCR Data From Paraffin-embedded Lymphoid Tissue. <i>Diagnostic Molecular Pathology</i> , 2009, 18, 243-249.	2.1	14
100	Myeloid neoplasm with prominent eosinophilia and <i>PDGFRA</i> rearrangement treated with imatinib mesylate. <i>Pediatric Blood and Cancer</i> , 2010, 55, 730-732.	1.5	14
101	Limited Efficacy of Hydroxyurea in Lowering of the JAK2 V617F Allele Burden.. <i>Blood</i> , 2008, 112, 1750-1750.	1.4	14
102	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Experimental and Molecular Pathology</i> , 2015, 99, 537-545.	2.1	13
103	<i>LPL</i> gene expression is associated with poor prognosis in <i>CLL</i> and closely related to <i>NOTCH1</i> mutations. <i>European Journal of Haematology</i> , 2016, 97, 175-182.	2.2	13
104	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688.	6.4	13
105	Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. <i>European Journal of Haematology</i> , 2018, 101, 585-590.	2.2	12
106	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , 2021, 108, 284-294.	6.2	12
107	Systemic mastocytosis--a systematic review. <i>Danish Medical Journal</i> , 2012, 59, A4397.	0.5	12
108	Pediatric Expression of Mast Cell Activation Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 365-377.	1.9	11

#	ARTICLE	IF	CITATIONS
109	<i>KIT</i> D816V Mutation-Positive Cell Fractions in Lesional Skin Biopsies from Adults with Systemic Mastocytosis. <i>Dermatology</i> , 2013, 226, 233-237.	2.1	10
110	Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1824-1836.	6.4	10
111	Targeted ultradeep next-generation sequencing as a method for <i>KIT</i> D816V mutation analysis in mastocytosis. <i>European Journal of Haematology</i> , 2016, 96, 381-388.	2.2	10
112	Molecular control of the cell cycle in cancer: biological and clinical aspects. <i>Danish Medical Bulletin</i> , 2003, 50, 118-38.	0.1	10
113	Systemic mastocytosis is uncommon in <i>KIT</i> D816V mutation positive core-binding factor acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1338-1344.	1.3	9
114	Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another "double hit" Lymphoma With Very Poor Outcome?. <i>Blood</i> , 2013, 122, 83-83.	1.4	9
115	Relationship of intratumoural protein expression patterns to age and Epstein-Barr virus status in classical Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 137-149.	2.2	8
116	Successful management of transfusion-dependent congenital dyserythropoietic anemia type 1b with interferon alpha-2a. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26866.	1.5	8
117	Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. <i>Blood Advances</i> , 2018, 2, 2533-2542.	5.2	8
118	Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2003, 74, 94-98.	4.1	7
119	Infantile Hemophagocytic Lymphohistiocytosis in a Case of Chediak-Higashi Syndrome Caused by a Mutation in the <i>LYST/CHS1</i> Gene Presenting With Delayed Umbilical Cord Detachment and Diarrhea. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e73-e79.	0.6	7
120	Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>British Journal of Haematology</i> , 2016, 174, 876-886.	2.5	7
121	Chronic lymphocytic leukemia patients with heterogeneously or fully methylated <i>LPL</i> promotor display longer time to treatment. <i>Epigenomics</i> , 2018, 10, 1155-1166.	2.1	7
122	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	6.2	7
123	Prognosis of localized diffuse large B-cell lymphoma in younger patients. <i>Cancer</i> , 2003, 98, 516-521.	4.1	6
124	Comparison of gDNA-based versus mRNA-based <i>KIT</i> D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis. <i>British Journal of Haematology</i> , 2017, 178, 330-332.	2.5	6
125	High intratumoural galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30 + PTCL-NOS. <i>Hematological Oncology</i> , 2020, 38, 59-66.	1.7	6
126	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6

#	ARTICLE	IF	CITATIONS
127	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	4.6	6
128	Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage.. <i>Apmis</i> , 2007, 115, 778-783.	2.0	5
129	Clinical validation of a new commercial highly sensitive <i>KIT</i> D816V mutation analysis in mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1489-1491.	5.7	5
130	IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load. <i>Haematologica</i> , 2022, 107, 877-886.	3.5	5
131	Myeloid Sarcoma Developing in Pre-existing Pyoderma Gangrenosum. <i>Acta Dermato-Venereologica</i> , 2008, 89, 175-177.	1.3	5
132	HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. <i>Transplantation Direct</i> , 2015, 1, e25.	1.6	4
133	Towards rational diagnostics in mastocytosis: clinical validation of sensitive <i>KIT</i> D816V mutation analysis of unfractionated whole-blood. <i>Leukemia and Lymphoma</i> , 2019, 60, 268-270.	1.3	4
134	Bone marrow histomorphology and <i>JAK2</i> mutation status in essential thrombocythemia. <i>Apmis</i> , 2007, 115, 1267-1273.	2.0	3
135	Relapse of myeloid neoplasm with eosinophilia and <i>PDGFRA</i> rearrangement after imatinib discontinuation in a pediatric patient. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2328-2328.	1.5	3
136	A child with mastocytosis and lymphomatoid papulosis. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 517-519.	0.5	3
137	Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for <i>SOX4</i> . <i>Scientific Reports</i> , 2021, 11, 19092.	3.3	3
138	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	1.4	3
139	Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia. <i>Cancers</i> , 2021, 13, 5526.	3.7	3
140	Differential protein expression of peroxiredoxin-1 in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. <i>Hematological Oncology</i> , 2015, 33, 253-255.	1.7	2
141	Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma. <i>Aids</i> , 2017, 31, 2311-2313.	2.2	2
142	Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma. <i>Leukemia Research Reports</i> , 2021, 15, 100255.	0.4	2
143	Intratumoral expression of CD38 in patients with post-transplant lymphoproliferative disorder. <i>Acta Oncologica</i> , 2021, 60, 1637-1642.	1.8	2
144	Primary thymic extranodal marginal zone B cell lymphoma as an incidental finding in a Caucasian woman. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211469.	0.5	2

#	ARTICLE	IF	CITATIONS
145	Poor Survival Predicted by MDM2 Oncoprotein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Wild-Type TP53 Gene. <i>Blood</i> , 2008, 112, 5269-5269.	1.4	2
146	A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis. <i>Blood</i> , 2014, 124, 2973-2973.	1.4	2
147	Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S216.	0.4	1
148	Venom anaphylaxis can mimic other serious conditions and disclose important underlying disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 338-339.	1.0	1
149	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. <i>Blood</i> , 2019, 134, 5092-5092.	1.4	1
150	Minimal Residual Disease and Normalization of the Bone Marrow after Long-Term Treatment with Alpha-Interferon2b in Polycythemia Vera. A Report on Seven Patients in Sustained Complete Hematological Remission with Major Molecular Responses.. <i>Blood</i> , 2008, 112, 1744-1744.	1.4	1
151	miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A, and MIR34B/C. <i>Blood</i> , 2012, 120, 296-296.	1.4	1
152	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 544-544.	1.4	1
153	Tumor Microenvironmental Features and Outcome in Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2014, 124, 1617-1617.	1.4	1
154	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 143-143.	1.4	1
155	Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1499-1499.	1.4	1
156	Diagnosis, treatment, and outcome of primary CNS lymphoma—a single-center experience. <i>Acta Neurochirurgica</i> , 2022, , 1.	1.7	1
157	A5.27â€¦Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A40.2-A40.	0.9	0
158	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S146-S147.	0.4	0
159	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S144-S145.	0.4	0
160	Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S220-S221.	0.4	0
161	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S228.	0.4	0
162	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S223.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Nuclear coexpression of NF- κ B subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S224.	0.4	0
164	Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma. <i>Leukemia Research</i> , 2019, 78, 1-2.	0.8	0
165	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. <i>Blood</i> , 2006, 108, 811-811.	1.4	0
166	Mutation in the Nucleophosmin Gene (NPM1) Is a Stable Marker for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients with Increased Sensitivity and Specificity Compared to Expression of the Wilms Tumor (WT1) Gene.. <i>Blood</i> , 2009, 114, 1602-1602.	1.4	0
167	Diffuse Large B-Cell Lymphoma. , 2011, , 1113-1116.		0
168	A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO. <i>Blood</i> , 2012, 120, 3651-3651.	1.4	0
169	miRNA Profiling Predicts Survival and Identifies a Novel Putative Oncomir in Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy. <i>Blood</i> , 2012, 120, 1548-1548.	1.4	0
170	NF- κ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 1620-1620.	1.4	0
171	Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Blood</i> , 2014, 124, 1623-1623.	1.4	0
172	Diffuse Large B-Cell Lymphoma. , 2016, , 1-6.		0
173	Diffuse Large B-Cell Lymphoma. , 2017, , 1366-1370.		0
174	Abstract 4359: Systematic approach to methylation biomarker development in chronic lymphocytic leukemia, breast and lung cancers. , 2017, , .		0
175	CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	1.3	0
176	A retrospective cohort study of patients with eosinophilia referred to a tertiary centre.. <i>Danish Medical Journal</i> , 2022, 69, .	0.5	0